使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Technologies Q3 2019 Earnings Conference. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to turn the conference over to your host, Shirley Stacy, Vice President, Corporate and Investor Communications. Thank you. You may begin.
各位好,歡迎參加 Align Technologies 2019 年第三季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。現在我很榮幸將會議交給今天的主持人:企業與投資人溝通副總裁 Shirley Stacy。謝謝。您可以開始。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Good afternoon, everyone, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued third quarter 2019 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on November 6. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13694915#, 16127415 with the same conference number.
謝謝。各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 GlobeNewswire 發布 2019 年第三季財務結果,可於 investor.aligntech.com 的網站上查閱。今天的電話會議將以音訊網路直播,並將在我們的網站上存檔約 12 個月。電話重播將於今日約下午 5:30(美東時間)提供,並持續至 11 月 6 日下午 5:30(美東時間)。如需收聽電話重播,美國境內來電者請撥打 (877) 660-6853,會議號碼 13694915#;16127415,會議號碼相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the fourth quarter of 2019. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2019 年第四季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We have posted historical financial statements, including the corresponding reconciliations and our third quarter 2019 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
我們已在網站「季度結果」專區公布歷史財務報表(包含相對應的調節表)以及 2019 年第三季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
With that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thank you for joining us. On our call today, I'll provide some highlights for the third quarter and briefly discuss the performance of our 2 operating segments, clear aligners and intra-oral scanners. John will provide more detail on our financial results and discuss our outlook for the fourth quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將提供第三季的一些重點,並簡要說明我們兩個營運部門——透明牙套與口內掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第四季展望。之後我會回來總結幾個關鍵重點,並開放提問。
For Q3, I'm pleased to report revenues, volumes and earnings above our third quarter outlook, driven by better-than-expected volume across the Invisalign portfolio in Asia Pacific and Latin America, reflecting record highs for both regions and improving trends in the North American orthodontics channel. Notwithstanding EMEA summer seasonality, we saw continued adoption from teens and especially young patients using Invisalign First across the board. Q3 Invisalign volumes were up 20.7% year-over-year, driven by the growth across the product portfolio as well as the expansion of our customer base, which increased by 5,900 new Invisalign doctors for a total of 63,000 active doctors worldwide.
第三季我很高興報告,我們的營收、出貨量與獲利均高於第三季展望;主要受惠於亞太與拉丁美洲地區 Invisalign 產品組合的出貨量優於預期,兩個地區皆創下歷史新高,且北美矯正通路的趨勢也在改善。儘管 EMEA 受到夏季季節性影響,我們仍看到青少年、尤其是使用 Invisalign First 的年幼患者持續採用。第三季 Invisalign 出貨量年增 20.7%,成長動能來自產品組合的擴張以及客戶基礎的擴大;新增 5,900 位 Invisalign 醫師,使全球活躍醫師總數達到 63,000 位。
The iTero scanner and services business was up 16.5% year-over-year, reflecting continued growth across each region, and down sequentially as expected coming off a record second quarter.
iTero 掃描器與服務業務年增 16.5%,反映各地區持續成長;但如預期般,因第二季創下歷史新高,第三季較前一季下滑。
Now let's turn to the specifics around our third quarter results, starting with the Americas region. For the Americas region, typical Q3 summer seasonality for adult case starts in North America was offset by the growth in North American teen market as well as the strength from Latin American orthodontists. Q3 Invisalign case volume was up 2% sequentially and 13% year-over-year on tough comps. Recall in Q3 '18, we had a teen and adult promotion that drove approximately 4 to 5 points of growth in the Americas.
接下來我們來看第三季結果的細節,先從美洲地區開始。在美洲地區,北美成人病例啟動數在第三季通常會有夏季季節性下滑,但被北美青少年市場的成長以及拉丁美洲矯正醫師的強勁表現所抵銷。第三季 Invisalign 病例量較前一季成長 2%,年增 13%,在高基期下仍有成長。回顧 2018 年第三季,我們曾推出青少年與成人促銷活動,為美洲地區帶來約 4 到 5 個百分點的成長。
In Q3, we trained over 2,700 new doctors in the Americas region, of which nearly half were Latin American doctors. On a sequential basis, Q3 Invisalign volume growth reflects increased utilization for the Americas region overall, driven by the North American Orthos at 19.1 cases per doctor, where we saw improved momentum throughout the quarter and good growth from teens in Invisalign First patients. North American GP volume was seasonally lower in Q3, and we're seeing improving trends into fourth quarter, reflecting benefit from our investment in sales resources added at the beginning of the year. New and existing reps are continuing to ramp up, and we would expect further progress over the remainder of the year.
第三季我們在美洲地區訓練了超過 2,700 位新醫師,其中近一半為拉丁美洲醫師。以季比來看,第三季 Invisalign 出貨量成長反映美洲地區整體使用率提升;主要由北美矯正醫師帶動,每位醫師平均 19.1 例,我們在整個季度看到動能改善,且青少年與 Invisalign First 患者帶來良好成長。北美一般牙醫(GP)在第三季因季節性因素出貨量較低;我們看到進入第四季的趨勢正在改善,反映年初新增銷售資源投資所帶來的效益。新舊業務代表持續上手並提升產能,我們預期今年剩餘期間將有進一步進展。
We also had continued strength across comprehensive and noncomprehensive products in Latin America led by Brazil. Year-over-year, Q3 Invisalign volume for the Americas region was driven by continued growth from both the Ortho and GP channels, including the DSOs. The DSO channel remains an important channel and consistently grows faster than non-DSO practices.
我們也看到拉丁美洲在完整療程與非完整療程產品上持續強勁,以巴西為首。以年比來看,美洲地區第三季 Invisalign 出貨量的成長,來自矯正與一般牙醫兩大通路(包含 DSO)持續成長。DSO 通路仍是重要通路,且其成長速度一貫快於非 DSO 診所。
For our international business, Q3 reflects increased growth in Asia Pacific, especially from our teen segment in China, partially offset by sequentially lower volume in EMEA due to the summer holidays for Invisalign practices in most European countries. On a year-over-year basis, Invisalign volume increased 32.1%, reflecting strength across our product portfolio with continued expansion of our customer base. In Q3, we changed -- we trained over 3,100 new Invisalign doctors internationally, with 60% in the Asia Pacific region.
在國際業務方面,第三季反映亞太地區成長加速,尤其是中國的青少年客群;部分被 EMEA 因多數歐洲國家 Invisalign 診所暑假而導致的季比出貨量下降所抵銷。以年比來看,Invisalign 出貨量增加 32.1%,反映我們產品組合的強勁表現以及客戶基礎持續擴張。第三季我們在國際市場訓練了超過 3,100 位新 Invisalign 醫師,其中 60% 位於亞太地區。
In EMEA, Q3 Invisalign volumes were down sequentially as expected, reflecting more pronounced seasonality in the first half of quarter and strong momentum in the back half led by Iberia and the U.K. Q3 volumes were up 29% year-over-year with broad-based growth across the Invisalign product portfolio and continued momentum from Invisalign Go treatment.
在 EMEA,第三季 Invisalign 出貨量如預期般較前一季下降,反映季度前半段季節性更為明顯;但後半段動能強勁,以伊比利亞半島與英國為首。第三季出貨量年增 29%,成長廣泛來自 Invisalign 產品組合,且 Invisalign Go 療程持續帶來動能。
We also continued to see strong growth across our key expansion markets as well led by Central and Eastern Europe and the Middle East and Africa. In Q3, as part of our corporate structure reorganization, we reallocated order acquisition for EMEA from the Netherlands to Poland. This site will serve as a centralized facility for order acquisition, local sales and support. In addition, this location will also offer treatment planning to support all of EMEA country markets except for Spain and Germany, where we'll continue to support their local markets.
我們也持續看到關鍵擴張市場的強勁成長,以中東歐以及中東與非洲為首。第三季,作為公司組織架構重整的一部分,我們將 EMEA 的訂單受理作業由荷蘭重新配置至波蘭。該據點將作為訂單受理、在地銷售與支援的集中化設施。此外,此地點也將提供治療規劃,以支援除西班牙與德國以外的所有 EMEA 國家市場;西班牙與德國我們將持續支援其在地市場。
For APAC, Q3 Invisalign volume increased 35.1% year-over-year led by Greater China and Japan. We continue to see strong growth from GP dentist, which was up 53.2% year-over-year, especially in Japan, where adoption of Invisalign Go continues to exceed expectations. On a sequential basis, Q3 Invisalign volume for APAC reflects continued momentum in China, especially from teen cases and growth from Taiwan and Korea. We also saw increased adoption of Invisalign First in Japan and ANZ and Taiwan as well as positive results from Teen Edge professional marketing programs, which are helping to drive Invisalign growth.
在亞太(APAC),第三季 Invisalign 出貨量年增 35.1%,主要由大中華區與日本帶動。我們持續看到一般牙醫(GP)強勁成長,年增 53.2%,尤其在日本,Invisalign Go 的採用持續超出預期。以季比來看,亞太第三季 Invisalign 出貨量反映中國動能延續,尤其是青少年病例,以及台灣與韓國的成長。我們也看到日本、澳紐(ANZ)與台灣對 Invisalign First 的採用增加,並且 Teen Edge 專業行銷計畫帶來正面成果,正協助推動 Invisalign 成長。
During the quarter, we opened the treatment planning facility in Yokohama, Japan, to better support Japanese doctors in local language and local time zones. APAC remains a huge growth opportunity for Align, and this investment reflects our commitment providing our customers with continued support as we grow and scale our business across the region.
在本季度,我們在日本橫濱啟用治療規劃設施,以便在當地語言與當地時區更好地支援日本醫師。亞太地區(APAC)仍是 Align 的重大成長機會,而這項投資反映了我們在區域內擴張並規模化業務的同時,持續為客戶提供支援的承諾。
Teens and kids continue to make up the largest portion of the orthodontic market and represent a huge growth opportunity for Invisalign treatment to replace metal braces worldwide. Over the past 2 years, we introduced 2 product innovations to help doctors treat more patients in this segment. Invisalign treatment with mandibular advancement addresses roughly 45% of teen cases and is the only clear aligner to move the mandible forward while straightening teeth at the same time. Invisalign First treatment is the first clear aligner product designed with features specifically for growing patients as young as 7 years old, and Phase 1 addresses 20% of the orthodontic case starts each year. Both products have continued to grow and helped increase utilization for Invisalign treatment worldwide.
青少年與兒童仍占矯正市場的最大比重,並代表 Invisalign 療程在全球取代金屬牙套的巨大成長機會。在過去 2 年中,我們推出了 2 項產品創新,協助醫師在此族群治療更多患者。具下顎前移功能的 Invisalign 療程可涵蓋約 45% 的青少年病例,且是唯一能在同時排齊牙齒的同時將下顎向前移動的透明牙套。Invisalign First 療程是首款專為最小可至 7 歲的成長期患者所設計、具特定功能的透明牙套產品,而第一期(Phase 1)每年約占矯正新開案的 20%。兩項產品皆持續成長,並有助於提升全球 Invisalign 療程的使用率。
In Q3, 130,000 teenagers and kids as young as 7 years old started treatment with Invisalign clear aligners, an increase of 31.5% year-over-year, reflecting continued adoption across all major regions, especially China. Cumulatively, nearly 2 million teens or younger patients have used Invisalign clear aligners.
在第三季,有 13 萬名青少年與最小至 7 歲的兒童開始使用 Invisalign 透明牙套進行治療,年增 31.5%,反映各主要地區(尤其是中國)持續採用。累計而言,已有近 200 萬名青少年或更年幼的患者使用過 Invisalign 透明牙套。
In Q3, we continue to see strong dental engagement with consumers, reaching over 4.5 million unique visitors on Invisalign websites worldwide for a total of 62 million visitors to date. Our digital approach to teen marketing continues to drive awareness and interested teenagers into Invisalign practices. Other key metrics show increased activity and engagement with the Invisalign brand and are included in our Q3 quarterly slides.
在第三季,我們持續看到消費者與牙科端的高度互動,全球 Invisalign 網站的獨立訪客超過 450 萬人,累計總訪客數迄今達 6,200 萬人次。我們以數位為主的青少年行銷方式,持續提升認知度,並將有興趣的青少年導入提供 Invisalign 的診所。其他關鍵指標亦顯示 Invisalign 品牌的活動與互動增加,並已納入我們第三季季度簡報投影片中。
In addition, we launched a new advertising campaign for North America at the beginning of the quarter. The North American campaign was launched across all key media channels with a reach to over 140 million consumers, combining a robust paid media strategy across prime broadcast, cable and connected TV channels with paid search and social media. While still new in the marketplace and very early in the cycle, we're seeing a positive response from doctors and consumers. In the last few weeks, all KPI metrics have shown strong momentum with more than a 50% increase in Doctor Locator searches and in leads scheduled from our Smile Concierge service.
此外,我們在本季度初於北美推出新的廣告活動。北美活動透過所有主要媒體渠道上線,觸及超過 1.4 億名消費者,結合在黃金時段無線電視、有線電視與連網電視(connected TV)渠道的強力付費媒體策略,以及付費搜尋與社群媒體。雖然在市場上仍屬新推出且仍在週期初期,我們已看到醫師與消費者的正面回饋。在過去幾週,所有 KPI 指標皆展現強勁動能,Doctor Locator 搜尋量以及透過我們 Smile Concierge 服務所安排的潛在客戶預約(leads scheduled)均增加超過 50%。
Finally, as many of you may have seen, we recently announced marketing relationships with several professional sports teams, including the San Francisco 49ers, the Toronto Raptors, the Carolina Hurricanes and the New England Patriots. Align is always looking for ways to evolve our brand marketing to be relevant to potential patients where they work, live and play.
最後,正如各位可能已看到的,我們近期宣布與多支職業運動隊伍建立行銷合作關係,包括舊金山 49 人隊、多倫多暴龍隊、卡羅萊納颶風隊以及新英格蘭愛國者隊。Align 一直在尋找方法,讓我們的品牌行銷持續演進,並在潛在患者工作、生活與休閒的場域中保持相關性。
Over the last few years, many sports brands have evolved their own brand programs to engage with fans in a variety of ways and through multiple touch points. Partnering with teams who have an omnichannel approach to brand marketing and engagement gives us direct access to large, loyal fan bases and helps us reach individual consumers and whole families through a variety of existing fan platforms. With the right team partners, we can create awareness for the power of winning smiles. And as always, the goal is the same for us: to build awareness and demand for Invisalign treatment and connect engaged consumers with Invisalign doctor practices in their markets.
在過去幾年,許多運動品牌已演進其品牌計畫,透過多種方式與多個接觸點與球迷互動。與採用全通路(omnichannel)品牌行銷與互動策略的球隊合作,讓我們能直接接觸龐大且忠誠的球迷族群,並透過各種既有的球迷平台觸及個別消費者與整個家庭。透過合適的球隊夥伴,我們能提升對「自信笑容」力量的認知。而一如既往,我們的目標不變:建立對 Invisalign 療程的認知與需求,並將高度互動的消費者與其所在市場的 Invisalign 醫師診所連結起來。
For Q3, iTero scanner and services revenue was down sequentially as expected and up 16.5% year-over-year, reflecting continued growth across all regions and customer channels, including large DSOs. Year-to-date, iTero revenues were up 47.3%, reflecting continued adoption of digital dentistry. Cumulatively, over 18 million orthodontic scans and 4.3 million restorative scans have started with iTero scanners. Heartland Dental, one of our largest DSO partners, recently celebrated their millionth iTero scan, highlighting how important iTero and Invisalign workflow is in their doctor practices, which now includes 900 offices across the U.S. and is enabling them to add nearly 200,000 digital scans per month.
第三季 iTero 掃描儀與服務營收如預期較前一季下滑,但年增 16.5%,反映所有地區與客戶渠道(包括大型 DSO)持續成長。年初至今,iTero 營收成長 47.3%,反映數位牙科持續被採用。累計而言,使用 iTero 掃描儀啟動的矯正掃描已超過 1,800 萬次,修復(restorative)掃描達 430 萬次。Heartland Dental 是我們最大的 DSO 合作夥伴之一,近期慶祝其第 100 萬次 iTero 掃描,凸顯 iTero 與 Invisalign 工作流程在其醫師診所中的重要性;其目前在全美已涵蓋 900 間診所,並使其每月可新增近 20 萬次數位掃描。
Use of iTero scanners for Invisalign case submissions continues to grow and remains a positive catalyst for Invisalign utilization. For Q3, total Invisalign cases submitted with a digital scanner in the Americas increased from 78.7% to 71.9% (sic) [to 78.7% from 71.9%] in Q3 of last year. International scans increased 62.5%, up from 53.9% in the same quarter last year. Within the Americas, 92.9% of cases submitted by North American orthos were submitted digitally. We continue to expand the iTero portfolio to address doctors' needs and enable them to more easily adopt Invisalign treatment in their practices.
使用 iTero 掃描儀提交 Invisalign 病例的比例持續成長,並仍是推動 Invisalign 使用率的正向催化因素。第三季,美洲地區以數位掃描儀提交的 Invisalign 病例總占比,較去年第三季由 71.9% 提升至 78.7%(原文誤植為「從 78.7% 到 71.9%」,應為[由 71.9% 至 78.7%])。國際市場的數位掃描占比提升至 62.5%,高於去年同季的 53.9%。在美洲地區,北美矯正專科醫師提交的病例中有 92.9% 以數位方式提交。我們持續擴充 iTero 產品組合,以滿足醫師需求,並讓他們在診所中更容易採用 Invisalign 療程。
In August, we announced the commercial availability of the iTero Element 2 scanner in China, with the first made in China iTero Element 2 produced in our manufacturing facility in Ziyang. The launch exemplifies Align's continued innovation and investment to advance digital dentistry in China.
8 月,我們宣布 iTero Element 2 掃描儀在中國正式商業供應,首台中國製 iTero Element 2 已在我們位於資陽的製造工廠生產。此次上市展現 Align 持續創新與投資,以推動中國數位牙科的發展。
In September, we were -- announced a global distribution agreement for the iTero Element family of intraoral scanners with Zimmer Biomet Dental. The agreement enables us to leverage Zimmer Biomet Dental's extensive direct global sales force and network of dental clinicians and laboratories to help to further drive the penetration of iTero scanners and services in the growing digital restorative market. The collaboration also offers Zimmer Biomet Dental customers access to Invisalign clear aligners through the iTero platform to facilitate a comprehensive interdisciplinary treatment approach.
9 月,我們——宣布與 Zimmer Biomet Dental 就 iTero Element 系列口內掃描儀簽訂全球經銷協議。該協議使我們得以運用 Zimmer Biomet Dental 龐大的全球直銷團隊,以及其牙科臨床醫師與實驗室網絡,進一步提升 iTero 掃描儀與服務在成長中的數位修復市場的滲透率。此合作亦讓 Zimmer Biomet Dental 的客戶可透過 iTero 平台取得 Invisalign 透明牙套,以促進更全面的跨專科整合治療方式。
We know that a key differentiator in the evolution to a digital practice and dental ecosystem is clinical education. Through this collaboration, the iTero scanner becomes the exclusive intraoral scanner used in the U.S. and European Zimmer Biomet Institutes, which trains thousands of doctors annually in an interactive learning environment, with the ultimate goal of improved clinical outcomes. We also joined Zimmer at the Japan Society of Oral Implantology Meeting in Japan and at the EAO in Portugal, where the iTero intraoral scanners were showcased.
我們知道,在邁向數位化診所與牙科生態系的演進中,關鍵差異化因素之一是臨床教育。透過此合作,iTero 掃描儀成為美國與歐洲 Zimmer Biomet Institutes 所使用的獨家口內掃描儀;該機構每年在互動式學習環境中培訓數千名醫師,最終目標是改善臨床結果。我們也與 Zimmer 一同參與日本口腔植體學會年會,以及葡萄牙的 EAO 會議,並展示 iTero 口內掃描儀。
With that, I'll now turn the call over to John.
接下來,我把電話會議交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q3 financial results. Total revenue for the third quarter was $607.3 million, up 1.1% from the prior quarter and up 20.2% from the corresponding quarter a year ago. Year-over-year revenue growth was favorable in all regions. For clear aligners, Q3 revenue of $516.3 million was up sequentially due to Invisalign volume growth in most geographies and higher ASPs. Year-over-year clear aligner revenue growth of 20.9% reflects strong Invisalign shipment growth across all customer channels and geographies and higher ASPs.
謝謝你,Joe。現在來看我們第三季的財務結果。第三季總營收為 6.073 億美元,較前一季成長 1.1%,較去年同期成長 20.2%。各地區的年增營收成長皆表現良好。就透明牙套而言,第三季營收為 5.163 億美元,因多數地區 Invisalign 出貨量成長及較高的平均售價(ASP),較前一季增加。透明牙套營收年增 20.9%,反映 Invisalign 在所有客戶渠道與各地理區域的出貨量強勁成長,以及較高的平均售價(ASP)。
Q3 Invisalign ASPs were up sequentially by approximately $30 to $1,260 primarily due to price increases in all regions, partially offset by promotional discounts. On a year-over-year basis, Q3 Invisalign ASPs were up $30 primarily reflecting price increases in all regions, partially offset by promotional discounts and unfavorable foreign exchange.
第三季 Invisalign 平均售價(ASP)較前一季上升約 30 美元至 1,260 美元,主要由於所有地區的價格上調,部分被促銷折扣所抵銷。以年對年來看,第三季 Invisalign ASP 上升 30 美元,主要反映所有地區的價格上調,部分被促銷折扣及不利的外匯影響所抵銷。
Total Q3 Invisalign shipments of 384 point -- 385,400 cases were up 2.2% sequentially and up 20.7% year-over-year. For Americas Orthodontists, Q3 Invisalign case volume was up 5.6% sequentially and up 16.4% year-over-year. For Americas GP Dentists, Invisalign case volume was down 4.1% sequentially and up 7.4% year-over-year. For international doctors, Invisalign case volume was up 2.5% sequentially and up 32.1% year-over-year. Our scanner and services revenue for the third quarter was $91.1 million, down 12.4% sequentially as expected, reflecting lower volume coming off another strong Q2, partially offset by higher ASPs. Year-over-year, scanners and services revenue was up 16.5%, driven by increased services revenue off a higher installed base and higher volume.
第三季 Invisalign 總出貨量為 384 點——385,400 例,較前一季增加 2.2%,年對年增加 20.7%。就美洲地區矯正專科醫師而言,第三季 Invisalign 病例量較前一季增加 5.6%,年對年增加 16.4%。就美洲地區一般牙醫(GP)而言,Invisalign 病例量較前一季下降 4.1%,年對年增加 7.4%。就國際醫師而言,Invisalign 病例量較前一季增加 2.5%,年對年增加 32.1%。第三季我們的掃描儀與服務營收為 9,110 萬美元,如預期較前一季下降 12.4%,反映在另一個強勁的第二季之後出貨量回落,部分被較高的 ASP 所抵銷。年對年而言,掃描儀與服務營收成長 16.5%,主要由於裝機基數提高帶動服務營收增加,以及出貨量提升。
Moving on to gross margin. Third quarter overall gross margin was 72%, flat sequentially and down 1.6 points year-over-year. Gross margin was impacted by approximately 0.3 points year-over-year due to unfavorable foreign exchange. Clear aligner gross margin for the third quarter was 73.5%, down 0.2 points sequentially primarily due to increased aligners per case, partially offset by higher ASPs and seasonally lower doctor training. Clear aligner gross margin was down 1.8 points year-over-year primarily due to increased aligners per case, partially offset by higher ASPs. Scanner gross margin for the third quarter was 64.1%, up 0.5 points sequentially and up 0.2 points year-over-year primarily due to higher ASPs and increased manufacturing efficiencies.
接下來談毛利率。第三季整體毛利率為 72%,較前一季持平,年對年下降 1.6 個百分點。由於不利的外匯因素,毛利率年對年約受到 0.3 個百分點的影響。第三季透明牙套毛利率為 73.5%,較前一季下降 0.2 個百分點,主要因每案使用的牙套數增加,部分被較高的 ASP 及季節性較低的醫師訓練成本所抵銷。透明牙套毛利率年對年下降 1.8 個百分點,主要因每案使用的牙套數增加,部分被較高的 ASP 所抵銷。第三季掃描儀毛利率為 64.1%,較前一季上升 0.5 個百分點、年對年上升 0.2 個百分點,主要由於 ASP 較高及製造效率提升。
Q3 operating expenses were $310.4 million, up sequentially 21.3% and up 25.9% year-over-year. The sequential increase reflects the benefit of $51 million related to the Straumann litigation settlement recorded in the second quarter. Additionally, the third quarter includes a $6.8 million benefit from the early termination of our Invisalign store leases. The year-over-year increase reflects our investment in consumer advertising with a brand-new North American campaign launched in August, continued -- and the continued investment in R&D, geographic expansion and go-to-market activities, partially offset by the benefit from the early termination of our Invisalign store leases.
第三季營業費用為 3.104 億美元,較前一季增加 21.3%,年對年增加 25.9%。前一季的增加反映第二季認列與 Straumann 訴訟和解相關的 5,100 萬美元利益。此外,第三季包含因提前終止我們 Invisalign 門市租約而帶來的 680 萬美元利益。年對年增加反映我們在消費者廣告上的投資——8 月在北美推出全新行銷活動——以及持續投入研發、地理擴張與上市推廣(go-to-market)活動;部分被第三季提前終止 Invisalign 門市租約所帶來的利益所抵銷。
Our third quarter operating income of $127.2 million resulted in an operating margin of 20.9%, down 8.5 points sequentially and down 3.9 points year-over-year. The sequential decrease in operating margin is primarily attributed to the $51 million benefit related to the Straumann settlement recorded in Q2, partially offset by a $6.8 million benefit related to the Invisalign store lease terminations in the third quarter. The year-over-year decrease in operating margin is primarily due to lower gross margin, as described earlier, and the increased investments in our geographic expansion and go-to-market activities, partially offset by the benefit from the early termination of our Invisalign store leases in the third quarter.
第三季營業利益為 1.272 億美元,營業利益率為 20.9%,較前一季下降 8.5 個百分點,年對年下降 3.9 個百分點。營業利益率較前一季下降主要歸因於第二季認列與 Straumann 和解相關的 5,100 萬美元利益,部分被第三季因 Invisalign 門市租約終止而帶來的 680 萬美元利益所抵銷。營業利益率年對年下降主要由於先前所述的毛利率較低,以及我們在地理擴張與上市推廣活動上的投資增加;部分被第三季提前終止 Invisalign 門市租約所帶來的利益所抵銷。
Operating margin was impacted by approximately 0.6 points year-over-year due to the unfavorable foreign exchange. Interest, other income and expense for the third quarter was $1.3 million, down $16.1 million sequentially and flat on a year-over-year basis. The sequential decrease reflects the $15.8 million gain related to the sale of our equity investment in SmileDirectClub during the second quarter.
由於不利的外匯因素,營業利益率年對年約受到 0.6 個百分點的影響。第三季利息、其他收入及費用為 130 萬美元,較前一季減少 1,610 萬美元,年對年持平。較前一季下降反映第二季出售我們在 SmileDirectClub 的股權投資所產生的 1,580 萬美元收益。
With regards to third quarter tax provision, our tax rate was 20.2%. Third quarter diluted earnings per share was $1.28, down $0.55 sequentially and up $0.04 compared to the prior year.
關於第三季所得稅費用,我們的有效稅率為 20.2%。第三季稀釋後每股盈餘為 1.28 美元,較前一季下降 0.55 美元,較去年同期增加 0.04 美元。
Moving on to the balance sheet. As of September 30, 2019, cash, cash equivalents and marketable securities, including both short- and long-term investments, were $782.4 million, an increase of $16.5 million from the prior quarter, which is primarily due to higher cash flow from operations, partially offset by $200 million used to repurchase approximately 1.1 million shares of our stock. Of our $782.4 million of cash, cash equivalents and marketable securities, $513.9 million was held in the U.S. and $268.5 million was held by our international entities. Q3 accounts receivable balance was $531.8 million, up approximately 2.3% sequentially. Our overall days sales outstanding was 79 days, up 2 days sequentially and up 4 days from Q3 last year.
接下來談資產負債表。截至 2019 年 9 月 30 日,現金、約當現金及有價證券(包含短期與長期投資)為 7.824 億美元,較前一季增加 1,650 萬美元,主要由於營運現金流增加,部分被用於回購約 110 萬股、合計 2 億美元的庫藏股所抵銷。在 7.824 億美元的現金、約當現金及有價證券中,5.139 億美元持有於美國,2.685 億美元由我們的海外實體持有。第三季應收帳款餘額為 5.318 億美元,較前一季約增加 2.3%。整體應收帳款週轉天數(DSO)為 79 天,較前一季增加 2 天,較去年第三季增加 4 天。
Cash flow from operations for the third quarter was $234.5 million, up $138.3 million compared to the prior year. Capital expenditures for the third quarter were $26.6 million primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow for the third quarter defined as cash flow from operations, less capital expenditures, amounted to $207.9 million.
第三季營運活動現金流為 2.345 億美元,較去年同期增加 1.383 億美元。第三季資本支出為 2,660 萬美元,主要與我們持續投資以提升牙套產能與設施相關。第三季自由現金流(定義為營運活動現金流減資本支出)為 2.079 億美元。
During Q3 2019, we entered into and completed an accelerated stock repurchase agreement, ASR, to repurchase $200 million of our common stock, which was completed in September of 2019. We received a total of approximately 1.1 million shares for an average price of $176.61 per share. We have $200.5 million remaining available for repurchase under the May 2018 repurchase program.
在 2019 年第三季期間,我們簽訂並完成一項加速股票回購協議(ASR),以回購 2 億美元的普通股,並於 2019 年 9 月完成。我們共取得約 110 萬股,平均每股價格為 176.61 美元。在 2018 年 5 月的回購計畫下,我們仍有 2.005 億美元可供回購。
With that, let's turn to our Q4 outlook and the factors that inform our view, starting with the demand outlook. Q3 was a solid quarter, and momentum has continued to build into Q4, across all regions. For international, we expect Q4 volumes across to be up sequentially, reflecting strong uptick from EMEA, as doctors come back from summer holidays. For the Americas, we expect Q4 volumes to be up sequentially, reflecting growth across all key country markets as well as momentum in North American Ortho and GPs along with increased media spend and the launch of our new consumer advertising campaign, as Joe described earlier.
接著我們來看第四季展望,以及支撐我們觀點的因素,先從需求展望談起。第三季表現穩健,且動能在所有地區持續延伸至第四季。就國際市場而言,我們預期第四季量能將較前一季成長,反映 EMEA 的強勁回升,因醫師在暑假後回到工作崗位。就美洲市場而言,我們預期第四季量能將較前一季成長,反映所有主要國家市場的成長,以及北美矯正專科與一般牙醫的動能,再加上媒體投放增加與我們全新消費者廣告活動的推出,如 Joe 先前所述。
We expect our iTero business to be up sequentially in Q4 to reflect end of the year capital equipment purchases and investment in growing the iTero business across all regions.
我們預期 iTero 業務在第四季將較前一季成長,反映年底資本設備採購,以及在所有地區持續投資以擴大 iTero 業務。
With this as a backdrop, we expect the fourth quarter to shape up as follows. Invisalign case volume is expected to be in the range of 400,000 to 407,000 cases, up approximately 20% to 22% year-over-year. We expect Q4 revenue to be in the range of $640 million to $650 million, up approximately 20% to 22% year-over-year. Our Q4 revenue outlook assumes no SDC volume compared to the same quarter a year ago when aligner supply to SDC contributed about $5.8 million to revenue. We expect Q4 gross margin to be in the range of 71.7% to 72.4%.
在此背景下,我們預期第四季將呈現如下表現。Invisalign 病例量預計介於 400,000 至 407,000 例,年對年約成長 20% 至 22%。我們預期第四季營收介於 6.40 億至 6.50 億美元,年對年約成長 20% 至 22%。我們的第四季營收展望假設不包含 SDC 的出貨量;相較之下,一年前同季對 SDC 的牙套供應約貢獻 580 萬美元營收。我們預期第四季毛利率介於 71.7% 至 72.4%。
Q4 gross margin is up 0.4 points compared to Q3 as we expect continued improvements in our manufacturing efficiencies associated with higher volumes. We expect Q4 operating expenses to be in the range of $318 million to $323 million. Q4 operating margin should be in the range of 22% to 22.7%. Our effective tax rate is expected to be approximately 24%. Diluted shares outstanding is expected to be approximately $79.4 million, exclusive of any share repurchases. Taken together, we expect our Q4 diluted earnings per share to be in the range of $1.35 to $1.42. In addition, we expect to repurchase at least $100 million of our stock in the open market in Q4.
由於我們預期在更高出貨量帶動下,製造效率將持續改善,第四季毛利率較第三季提升0.4個百分點。我們預期第四季營業費用將介於3.18億至3.23億美元。第四季營業利益率應介於22%至22.7%。我們預期有效稅率約為24%。在不包含任何庫藏股回購的情況下,預期稀釋後流通在外股數約為7,940萬股。綜合以上,我們預期第四季稀釋後每股盈餘將介於1.35至1.42美元。此外,我們預期在第四季於公開市場至少回購1億美元的本公司股票。
As we continue our operational expansion efforts, we expect capital expenditures for Q4 to be approximately $30 million to $35 million, and we expect depreciation and amortization to be $22 million to $24 million.
隨著我們持續推動營運擴張,我們預期第四季資本支出約為3,000萬至3,500萬美元,並預期折舊與攤銷為2,200萬至2,400萬美元。
Before turning the call back to Joe, I want to update you on our corporate entity reorganization. On January 1, 2020, our EMEA headquarters in the Netherlands will officially move to Switzerland. Our new Swiss location will serve as the headquarters for all regional, commercial and operational activities in EMEA and will be supported by the existing network of local offices established across the region. Our new corporate entity, Align Technology Switzerland GmbH, will assume all responsibility for the sale and distribution of the Invisalign system, iTero intraoral scanners and associated Align goods and services in EMEA, previously provided by Align Technology B.V.
在把電話會議交回給Joe之前,我想向各位更新我們的公司法人實體重組進度。自2020年1月1日起,我們位於荷蘭的EMEA總部將正式遷至瑞士。我們在瑞士的新據點將作為EMEA所有區域、商務與營運活動的總部,並由該區域既有的在地辦公室網絡提供支援。我們新的公司法人實體 Align Technology Switzerland GmbH 將承擔在EMEA地區銷售與配送 Invisalign 系統、iTero 口內掃描儀及相關 Align 商品與服務的全部責任;此前上述業務由 Align Technology B.V. 提供。
Our local and global teens have been working diligently to ensure a very smooth transition while supporting our doctors, suppliers and employees, many of whom have decided not to relocate to Switzerland but will stay on in transitional roles as needed. I want to thank all of our employees for their hard work and dedication in supporting this major company initiative. While it is never easy to make this kind of change, especially when it impacts team members who have helped build the EMEA business and have contributed so much to our overall success, we are very excited about our new operations in Switzerland.
我們在地與全球團隊一直勤奮投入,以確保過渡非常順利,同時支援我們的醫師、供應商與員工;其中許多人已決定不搬遷至瑞士,但將視需要以過渡性職務繼續留任。我要感謝所有員工在支持這項重大公司計畫上的辛勤工作與投入奉獻。雖然做出這類改變從來不容易,尤其當它影響到曾協助建立EMEA業務、並為我們整體成功做出重大貢獻的團隊成員時,但我們對於在瑞士的新營運據點感到非常振奮。
Now I'll turn the call back to Joe for closing comments.
現在我把電話會議交回給Joe作結語。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John, and thanks for joining our call today. Overall, Q3 was a solid quarter for us across the board with increasing momentum in APAC and North America that has carried us over into Q4. As you can see from the high end of our guidance, the implied full year growth rate from Invisalign volume is 23.5%, with international growth in the mid to high 30s.
謝謝你,John,也謝謝各位今天參與我們的電話會議。整體而言,第三季對我們來說各方面都是穩健的一季,亞太與北美的動能持續增強,並延續到第四季。如各位從我們財測區間的高端所見,Invisalign 出貨量所隱含的全年成長率為23.5%,其中國際市場成長率約在30%中段至高段。
Overall, our business remains very healthy with numerous growth drivers in a vastly underpenetrated market. We remain confident in both the enormous opportunity ahead to lead the evolution of digital orthodontics and comprehensive dentistry with our doctor customers, and in our ability to execute our strategy to increase adoption of Invisalign treatment globally.
整體而言,我們的業務仍非常健康,在一個滲透率仍極低的市場中擁有多項成長動能。我們對於未來龐大的機會仍充滿信心:一方面可與我們的醫師客戶共同引領數位矯正與全方位牙科的演進;另一方面也有信心執行我們的策略,在全球提升 Invisalign 治療的採用率。
With that, I want to thank you again for joining the call. I look forward to seeing many of you at our upcoming financial conferences and meetings, including the Invisalign GP Summit in November in Las Vegas. Operator?
最後,再次感謝各位參與本次電話會議。我期待在接下來的財務研討會與會議上見到各位,包括11月在拉斯維加斯舉行的 Invisalign GP Summit。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from Erin Wright with Crédit Suisse.
(接線員指示) 我們的第一個問題來自瑞士信貸(Crédit Suisse)的 Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
In terms of the higher OpEx spend, are you seeing the returns from the North America, I guess, stepped-up marketing and media spend as you expected? And how should we be thinking about that level of spend into the fourth quarter just based on the responses that you're seeing from the marketing campaigns so far? And will this, I guess, contribute to the accelerating kind of volume trends in the fourth quarter as well as momentum into 2020?
就較高的營業費用支出而言,你們是否如預期看到北美(我想是)加碼的行銷與媒體投放帶來的回報?另外,基於目前行銷活動的回應情況,我們應該如何看待第四季的支出水準?以及這是否也會促成第四季出貨量趨勢加速,並延續動能到2020年?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Erin, it's Joe. Yes, we're seeing, as you can tell from the statistics we just recorded, we have a real large take-up when you think about doc locator searches, which is a primary or concierge service and what they're handling. Remember, the concierge service takes those customers and then directs them directly to doctors that we have a high degree of certainty that they'll actually convert them into Invisalign.
Erin,我是Joe。是的,我們確實看到成效;從我們剛才提到的統計數據你也看得出來,當你看醫師定位器(doc locator)的搜尋量時,我們的採用率非常高,而這是主要的(或禮賓式)服務之一,也是他們在處理的內容。請記得,禮賓服務會接手這些客戶,然後把他們直接導向我們相當有把握能夠把他們轉化為 Invisalign 病患的醫師。
As we move into the fourth quarter, expect the same amount of investment. Also in the Americas too with the improvements you're seeing is also our sales force and the additions we put together. As we said at the beginning of the year, it usually takes at least 9 months, 6 to 9 months, to see some kind of traction that we're seeing with the sales force, too. So both the advertisements from a North America standpoint and the added salespeople, we think, are really contributing to that momentum we just reported.
進入第四季,我們預期投資金額會維持相同水準。另外,在美洲地區,你看到的改善也來自我們的銷售團隊以及我們所增補的人力。如同我們在年初所說,通常至少需要9個月、約6到9個月,才能在銷售團隊上看到我們目前所見到的這種牽引力。因此,無論是北美的廣告投放,或是新增的銷售人員,我們認為都確實在推動我們剛才所報告的那股動能。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Okay. Great. And then my follow-up, just on China, in particular. Can you speak to what you're seeing across that market, just given some of the commentary you had in the previous quarter around the softness in that geography? If you could give us an update there, that would be great.
了解。很好。那我追問一下,特別是關於中國。鑑於你們上一季對該地區需求偏弱的評論,你能談談你們在那個市場目前看到的情況嗎?如果能給我們一個最新進展就太好了。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, the momentum we reported in China that we -- when we had our announcement in the second quarter, continued throughout the quarter. So I think we had 26% growth in China in the second quarter. As we move into the third quarter, we're in the upper 30% range.
嗯,我們在中國所報告的動能——也就是我們在第二季發布公告時提到的——在整個季度都持續延續。所以我想我們第二季在中國的成長是26%。進入第三季,我們的成長落在30%高段。
Overall, we're just seeing good uptake. We had a good teen season there. We've hired 40% more people in China also. It takes them a while to actually become acclimatized, be trained and have them effective in China also. So we feel good about the momentum in China.
整體而言,我們看到良好的採用提升。我們在那裡的青少年旺季表現不錯。我們也在中國增聘了40%的人力。他們也需要一些時間來適應、受訓,並在中國發揮效能。因此我們對中國的動能感到樂觀。
I think the economic situation there with reporting the slowest growth we've seen in 30 years, we know we have a headwind there because that continues, it reported in the second quarter, too. But overall, we think we've made the right adjustments and we have the right focus right now to continue some good growth there.
我認為那裡的經濟情勢——報告顯示為30年來最慢的成長——我們知道這會帶來逆風,因為這種情況仍在持續,第二季也有報告到。但整體而言,我們認為我們已做出正確調整,而且目前聚焦方向正確,能夠在那裡持續取得不錯的成長。
Operator
Operator
Our next question comes from Steve Beuchaw with Wolfe Research.
下一個問題來自 Wolfe Research 的 Steve Beuchaw。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
I'm sure there'll be a lot of questions about Invisalign and appropriately so so I want to go a different direction and ask about a couple other things.
我相信會有很多關於 Invisalign 的問題,而且這也很合理,所以我想換個方向,問幾個其他方面的問題。
One is actually the iTero number in the quarter. I know it's normal seasonally to see things make a move like this, but I wonder, as you saw trends for iTero in the quarter, where -- there was actually a lot going on operationally, given what you were doing with Zimmer, which I'm sure was a significant time investment for the sales force where you had a product launch coming in a key region. Do you think there was any disruption in terms of the commercial effort around iTero during the quarter?
其中一個其實是本季 iTero 的數字。我知道從季節性來看,出現這樣的變動很正常,但我想問的是,當你們觀察本季 iTero 的趨勢時——在營運面其實同時發生了很多事,考量到你們與 Zimmer 的合作(我相信這對銷售團隊而言是相當大的時間投入),以及你們在一個關鍵區域進行產品上市——你認為本季在 iTero 相關的商務推進上,是否有任何干擾?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Steve, it's John. No, there's no disruption. I mean we are -- if you look at iTero for -- on a year-to-date basis, it's up 47%. You're going to have some timing that happens by quarter, but we feel very good where iTero is. It's the front end of our digital ecosystem, very critical to our business, and you're going to have fluctuations by quarter. But we feel very good where iTero is so far this year.
Steve,我是John。不,沒有中斷。我的意思是,我們——如果你看iTero——以年初至今來看,成長了47%。按季度來看會有一些時點上的影響,但我們對iTero目前的表現感到非常滿意。它是我們數位生態系統的前端,對我們的業務非常關鍵,而且你會看到按季度的波動。但就今年迄今為止而言,我們對iTero的狀況感到非常好。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
Okay. And then sorry, Joe, for leaving you out here, but I got a couple for John. One is on the transition in Europe, can you speak to how much duplicative costs you might be -- might have been carrying between the Switzerland operations and the Netherlands operations and what that could mean for the tax rate over time as you change the domicile of the organization. And then I wonder if you could give us an update on what you think prospectively the impact of facilities' manufacturing capacity utilization is going to be going forward on gross margins?
好的。然後抱歉,Joe,剛剛把你晾在一旁了,但我有幾個問題想問John。第一個是關於歐洲的轉換,你能否談談在瑞士營運與荷蘭營運之間,你們可能——或曾經——承擔了多少重複成本?以及隨著你們變更組織的註冊地(domicile),這對長期稅率可能意味著什麼。另外,我想請你更新一下,展望未來,廠房製造產能利用率對毛利率的影響會是什麼?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Steve. In terms of the changes that we make and making in EMEA, it's really to simplify some of the organization that we have and in light of many of the tax changes and other structures that we had to create. So look at it from that standpoint. It simplifies things a little bit from an entity standpoint and gives us some flexibility to changes to our tax -- to taxes that happen globally.
是的,Steve。就我們在EMEA所做以及正在做的變更而言,主要是為了簡化我們現有的一些組織架構,並且考量到許多稅制變動以及我們不得不建立的其他架構。所以可以從這個角度來看。從法人實體的角度來說,這讓事情更簡化一些,也讓我們在面對全球稅務變動時,對我們的稅務——對稅制變化——有一些彈性。
From a facility standpoint, we're putting in manufacturing where it makes sense. We've talked a lot about China manufacturing, and that continues to ramp up. Treatment planning globally would be closer to our customers. That's very important to us. And there's always a transition period in terms of that productivity, as they become more and more productive, but we feel very good about the investments that we've made and the gross margin that we see now and what we're forecasting.
就廠房而言,我們會在合理的地方佈建製造。我們談了很多中國製造,而那也持續在爬坡提升。全球的治療規劃會更貼近我們的客戶。這對我們非常重要。而在生產力方面總會有一段過渡期,隨著他們變得越來越有效率,但我們對已做出的投資、目前看到的毛利率,以及我們的預測都感到非常有信心。
Operator
Operator
Our next question comes from John Kreger with William Blair.
下一個問題來自William Blair的John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, what's your sense about the underlying health of consumer spending on orthodontics at this point? Is it getting better or worse? And I'm curious if you think the -- all the money going into some of the direct-to-consumer-oriented models like SDC, is that proving to be a net benefit to Align or a little bit of a detriment as you weigh sort of awareness versus any competitive shifts?
Joe,你對目前矯正相關的消費者支出基本面健康狀況有何看法?是在變好還是變差?另外我也好奇,你認為——大量資金投入到一些以直面消費者(DTC)為導向的模式(例如SDC),對Align而言,整體是淨利多,還是當你權衡品牌認知提升與任何競爭態勢變化時,反而有些負面影響?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, first of all, I think you picked up in your survey and other people do too when we pick it up is, I mean we see good consumer spending right now from an orthodontic standpoint. Align stands out in that spending when you look at it specifically. As far as how that's driven, obviously we've put a lot more into consumer advertising, and some of the DTC competitors have done that also. I do think that, that raises consumer brand awareness. No question. I think the consumers go to the Internet to try to answer those questions. They'll go to their doctors to try to answer those questions, too. So I can't deny, John, I think that our advertising and some competitive advertising in that sense probably does raise all boats to a certain extent.
John,首先,我想你在你的調查中也注意到了,我們在觀察時其他人也有同樣的感受:就矯正而言,我們目前看到消費者支出表現不錯。當你特別去看時,Align在這些支出中表現突出。至於這是如何被帶動的,顯然我們在消費者廣告上投入更多,一些DTC競爭對手也同樣如此。我確實認為,這會提升消費者的品牌認知。毫無疑問。我認為消費者會上網嘗試找到答案。他們也會去找醫師嘗試得到答案。所以我不能否認,John,我認為我們的廣告以及某種程度上的競爭性廣告,確實可能在一定程度上帶動整體市場水位上升。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. And then one quick follow-up. The utilization among your North American GPs has been kind of flat over the last couple of years. What is your thinking about the best way to drive that higher over the next year or 2?
很好。再追問一個。過去幾年,你們北美一般牙醫(GP)的使用率大致持平。你認為在未來1到2年,推動它提升的最佳方式是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
First of all, John, I think you know that. You've been with us for a long time. We add so many GPs every year. 150,000 of them, we train significant numbers of them each year. And so you end up with a dilutive effect in that sense. So the numbers that we reported, it always is around 3.4% to 3.6% from quarter-to-quarter. But back to your question, I think the way to do this is: one, obviously, our DSO approach is a good one because as I talked about it being a force multiplier before you work with these strong DSOs, they have their own training for their groups.
首先,John,我想你是知道的。你跟我們很久了。我們每年新增很多GP。大約15萬名,我們每年訓練其中相當多的人。因此在那個意義上,你最後會看到稀釋效應。所以我們所報告的數字,從季度到季度通常都在3.4%到3.6%左右。但回到你的問題,我認為做法是:第一,顯然,我們的DSO策略是好的,因為如我之前談到的,與這些強勢DSO合作能產生乘數效應,他們也會為其團隊提供自己的訓練。
They help quantify workflow and do different things that for years in this business, I think we thought we just needed one product, but we've learned over time, like a product like iGo really isn't a product, it's a system. It's a system that really works with GPs to identify patients that qualify for this. It fits well with their workflow. It allows them to be confident when they're in front of patients that they can handle those cases, and we stand behind them. So overall, it's right products, right systems, working with DSOs that help us to become -- drive better penetration, too.
他們協助量化工作流程並做各種不同的事情;在這個產業多年來,我想我們曾以為只需要一個產品,但我們隨著時間學到的是,像iGo這樣的產品其實不是單一產品,而是一個系統。這是一個真正能與GP合作、用來辨識符合條件患者的系統。它很契合他們的工作流程。它讓他們在面對患者時更有信心,知道自己能處理那些病例,而我們也會在背後支持他們。所以整體而言,就是正確的產品、正確的系統,再加上與能協助我們——也推動更高滲透率——的DSO合作。
Operator
Operator
Our next question comes from Ravi Misra with Berenberg Capital Markets.
下一個問題來自Berenberg Capital Markets的Ravi Misra。
Ravi Misra - Analyst
Ravi Misra - Analyst
Can hear me okay?
聽得到我嗎?
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Yes. Sure.
聽得到。當然。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great. So just a question on the gross margin, not to pick too much at what I think was a pretty good quarter, just why aren't we seeing, given the kind of pricing uptick that looks like it emerged in the third quarter, why aren't we seeing more of a flow-through on the clear aligner gross margin in the fourth quarter? And maybe if you could help us think about pricing in the fourth quarter for the ASPs. I think last quarter, you said it would be about even with the second quarter, and that's pretty much a lot better than that. So do you feel more confidence in your ability to take price here?
很好。我想問一個關於毛利率的問題,不是要過度挑剔——我認為這是一個相當不錯的季度——只是想問,考量到第三季似乎出現的那種價格上調,為什麼我們在第四季沒有看到更多在透明牙套毛利率上的傳導(flow-through)?另外,也許你可以幫我們思考第四季ASP的定價。我記得上季你說大概會與第二季差不多,而實際上好很多。所以你對在這裡提價的能力是否更有信心?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Robbie, this is John. As we've discussed, I mean we've taken price up in the third quarter, and you see that show up in ASPs. We're also investing to -- in our manufacturing and treatment plant to be closer to our customers. Sometimes that offsets -- and in third quarter, there was not much change from Q2. In Q4, we talked about our guidance, which is up sequentially in gross margin. It's a reflection of more volume productivity that we expect to continue to see at these manufacturing sites. And we'll continue to see that benefit. When you look at the ASPs, as you mentioned, like I said, at $1,260, was a good increase of $30 from Q2. We were able to -- when we think about the forecast to that, it will come down slightly. The mix was really high from a comprehensive standpoint in Q3. So when we take it down to Q4, it'll be, we think, closer to $1,245, which is very consistent that we've talked about as being essentially flat as we go through this year.
是的。Robbie,我是John。如我們討論過的,我們在第三季提高了價格,你也看到這反映在ASP上。我們也在投資——在我們的製造與治療規劃廠——以便更貼近我們的客戶。有時候這會抵銷——而在第三季,與第二季相比變化不大。在第四季,我們談到的指引是毛利率將較前一季提升。這反映出我們預期在這些製造據點會持續看到更多的量產帶來的生產力提升。而我們也會持續看到那樣的效益。至於ASP,如你提到的,我之前說過,1,260美元相較第二季增加30美元,是一個不錯的提升。當我們思考對此的預測時,它會略微下滑。第三季在綜合型(comprehensive)方面的組合占比非常高。所以到第四季時,我們認為會更接近1,245美元,這與我們一直以來所談到的——也就是今年走下來基本持平——非常一致。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great. And then if I can just maybe squeeze in a follow-up to the implications on teen there with the comprehensive, just if you could confirm or maybe provide some color. As that -- as you get deeper penetration in that market, it looks like you've been doing 30% growth here the last few quarters. How should we think about the mix shift on the pricing? That should be kind of a good guy, right, with the more comprehensive cases?
很好。接著如果我可以再追問一下關於青少年那邊、以及全面性(comprehensive)方案所帶來的影響,想請你確認或提供一些補充說明。隨著你們在那個市場的滲透率加深,看起來你們過去幾個季度在這裡維持約30%的成長。我們應該如何看待定價上的組合轉移(mix shift)?在更全面性的病例占比提高下,這應該算是利多,對吧?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Rob, it's Joe. Yes, you're right. It's a mix shift. Remember, from a teen growth standpoint, and we're reporting really good above 30% teen growth globally, but we're still the -- our utilization rates in that marketplace are way below our clinical entitlement, I would say. Today, we can handle almost all teen cases. So with that in mind, though, it is a mix-up. It is primarily a comprehensive marketplace. It's primarily an ortho marketplace in how it works. We feel really good about our portfolio to be able to address the teen patients right now. And long term, we see that as a counterbalance on ASPs that we all think about.
是的,Rob,我是Joe。是的,你說得對。這是一個組合轉移。請記得,從青少年成長的角度來看,我們在全球回報的青少年成長率確實高於30%,但在那個市場,我們的使用率仍遠低於我們在臨床上可承接的範圍(clinical entitlement),我會這麼說。以今天來看,我們幾乎可以處理所有青少年病例。因此在這個前提下,確實是組合上的變化。那主要是一個全面性方案的市場。就其運作方式而言,主要也是一個齒顎矯正(ortho)市場。我們對於目前能以產品組合來服務青少年患者感到非常有信心。長期來看,我們認為這會在我們都會關注的ASP(平均售價)上形成一個平衡力量。
Operator
Operator
Next question is from Jon Block with Stifel.
下一個問題來自Stifel的Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Joe, maybe first one for you. Just any comments, maybe I missed it, but sort of on comprehensive versus non-comprehensive growth this quarter. And then with the GP summit approaching next month, is there any plan to more aggressively sort of pursue, call it, this lower acuity cases through that channel? And then I've got a follow-up.
Joe,第一個問題可能先問你。關於本季全面性(comprehensive)與非全面性(non-comprehensive)的成長,你有沒有什麼評論?也許我漏聽了。另外,下個月GP高峰會(GP summit)即將到來,你們是否計畫透過這個通路更積極地推進、我稱之為較低複雜度(lower acuity)的病例?我還有一個追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean Jon, honestly, I mean from a comprehensive standpoint obviously still 70% of our portfolio more goes that way. But with the introduction of Lite, iGo, products like this, we made an adjustment on E5 this quarter, E7, all these other products. I mean that part of our product line has traditionally been growing faster and with the comprehensive thing is. Now it's a law of small numbers versus large numbers, but we do see increased growth in that area.
是的。Jon,老實說,從全面性方案來看,顯然我們的產品組合中仍有70%是走這個方向。但隨著Lite、iGo等產品的推出,我們本季也對E5、E7以及其他產品做了調整。我們這一段產品線傳統上成長速度一直比全面性方案更快。當然這也有小數法則對比大數法則的因素,但我們確實看到那個領域的成長在加速。
When we look at the GP channel, we do look at the GP channel as a way to get at patients, what we call kind of a sub-acute kind of on a patient base to do that. So I mentioned iGo on the last call also as being a system that allows us to do that. Obviously, Lite does that also. So you'll see us, Jon, increasingly focused on that channel, but also think about working really closely with GPs on not just the product line, but the system itself with iTero, how to be able to do treatment planning quickly and to give the GPs confidence that when they adopt these cases, that they'll finish and they'll finish well. Those are the 3 critical variables we know we have to hit to really drive significant growth.
當我們看GP通路時,我們確實把GP通路視為接觸患者的一種方式,去服務我們所稱的較次急性(sub-acute)類型患者族群。所以我在上次電話會議也提到iGo,它是一個讓我們能做到這件事的系統。顯然Lite也能做到。因此你會看到我們,Jon,會越來越聚焦在這個通路;同時也會思考如何與GP更緊密合作,不僅是在產品線上,也包括iTero這套系統本身,如何能快速完成治療規劃,並讓GP有信心:當他們接下這些病例時,能夠完成治療,而且完成得很好。我們知道要真正推動顯著成長,必須達成這3個關鍵變數。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Got it. Very helpful. And then just maybe John, the reorg for this year, is there sort of a refined number? Is that 1.5% or 2%? Or is it still in that range? And then sort of part B to that question is it follows up on Ravi's. Just to be as specific as possible, the gross margin is in sort of flattish Q3 to Q4, is it a globalizing the supply chain headwind? Or is it more aligners per case headwind? And I'm asking that because the more aligners per case, that probably continues with teen, et cetera, but the globalizing supply chain, that seems more of a '19 event than a '20 event. So any more detail you can give around gross margin would be helpful.
了解。非常有幫助。接著可能問John,今年的重組(reorg),是否有更精確的數字?是1.5%或2%?還是仍在那個區間?另外這個問題的第二部分是延續Ravi的提問。盡可能具體地說,毛利率在Q3到Q4大致持平,是因為供應鏈全球化(globalizing the supply chain)的逆風?還是每個病例所需的牙套數(aligners per case)增加的逆風?我之所以這樣問,是因為每案牙套數增加,可能會隨著青少年等因素持續;但供應鏈全球化看起來更像是2019年的事件,而不是2020年的事件。所以若能提供更多毛利率相關細節會很有幫助。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Jon, it's really both. I mean when you look at, especially as we do and work with our doctors doing more and more complicated cases, as comprehensive grows and Invisalign First and teen and so on, those end up being more aligners and end up impacting our gross margin.
是的,Jon,兩者都有。我的意思是,尤其當我們與醫師合作處理越來越多複雜病例時,隨著全面性方案成長、以及Invisalign First、青少年等產品推進,這些通常會需要更多副牙套(aligners),並對我們的毛利率造成影響。
The globalization that we're doing, that's much more short term. As we said, getting close to our customers is very, very critical to us. Treatment planning, manufacturing. But as you get more and more capacity there and scale that, you see productivity improvements.
我們正在做的全球化布局,那比較偏短期。如同我們所說,貼近客戶對我們非常、非常重要。包括治療規劃、製造。但當你在當地建立越來越多產能並擴大規模時,就會看到生產力的改善。
Operator
Operator
Our next question is from Kevin Caliendo with UBS.
下一個問題來自UBS的Kevin Caliendo。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Kevin, you there?
Kevin,你在線上嗎?
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Yes. Sorry, I apologize. Did you take the same price increases internationally as you did domestically? That's the first quick one. And then just looking at the trend, quarterly trend in case growth and overall revenue growth, is seasonality shifting as international sales grow as a percentage? And how should we think about that going forward?
在。抱歉,不好意思。你們在國際市場的漲價幅度,和美國本土一樣嗎?這是第一個快問。另外,從病例量成長與整體營收成長的季度趨勢來看,隨著國際銷售占比提高,季節性是否正在改變?我們未來應該如何看待?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Kevin, Joe. On the pricing piece, yes, it's about the same. I think there's some [nips and tucks] on Lite versus comprehensive. But basically the same price increase globally across the board.
Kevin,我是Joe。關於定價部分,是的,差不多。我想在Lite相對於全面性方案上有一些小幅調整([nips and tucks])。但基本上全球各地整體的漲價幅度大致一致。
On the revenue growth, the seasonality of it. I think the biggest thing that you can think of, there's really a couple of trends in this business is, one, in North America, you move into the third quarter, it's teen season and GPs tend to decline. But the biggest mix is in Europe, where you basically go down for vacation, I mean lights go out for us for a long period of time, and then obviously come back in September. And then you got China on the other side that kind of compensates for that in the past. So those are the big, I would say, countercyclical or cyclical movements that we have in the business.
至於營收成長與季節性。我認為你可以思考的最大重點是,這個業務其實有幾個趨勢:第一,在北美進入第三季時,是青少年旺季,而GP(一般牙醫)通常會下滑。但最大的組合因素在歐洲,因為基本上大家去度假,我是說對我們而言會有很長一段時間幾乎停擺,然後在9月明顯回來。另外,中國在另一端,過去某種程度上會對此形成補償。所以我會說,這些就是我們業務中主要的反向循環(countercyclical)或循環性(cyclical)波動。
Operator
Operator
Our next question comes from Richard Newitter with SVB Leerink.
下一個問題來自SVB Leerink的Richard Newitter。
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
I have 2, Joe. Just the first one. Just last quarter, you gave a little bit of color on anecdotally what you're seeing out in the field from doctor-directed competition and some of the discounting that might be taking place. I was just curious if you could comment on the -- on the trend into the current quarter and what you're seeing there? Anything that's surprising you or different from what you saw last quarter on those? And I have a follow-up.
Joe,我有兩個問題。第一個是,上個季度你有稍微分享一些一線觀察,關於由醫師主導的競爭(doctor-directed competition)以及可能出現的一些折扣。我想請問你能否評論一下進入本季度的趨勢,以及你目前看到的情況?在這方面,有沒有任何讓你意外的地方,或與上季看到的不同?我還有一個追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Richard, on the -- with that comment I made last quarter had to do with doctor-directed to DYI model and primarily North America and some kind of young adult segments. We actually saw that stabilize and actually start to improve in the third quarter from an order end point. So actually saw good momentum in the right direction there.
Richard,關於我上季的那段評論,是針對由醫師主導、對比DIY模式的競爭,主要在北美以及一些年輕成人族群。我們其實看到那個情況趨於穩定,並且在第三季從訂單端來看開始改善。所以我們確實看到那邊朝正確方向有不錯的動能。
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Okay. And I was just referring to the more traditional competitors that recently started launching products where there might be some trialing. That's what you're referring to as improving, not the DTC...
好的。我只是指那些較傳統的競爭對手,最近開始推出可能還在試行階段的產品。你所說的改善是指這個,而不是 DTC……
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
No. Actually, I'd say both. I mean the traditional competitors that are out there, we acknowledged them last quarter, which we thought we had to, but there's no fundamental change in that, what we saw in the second quarter versus what we saw in the third quarter.
不是。其實,我會說兩者都是。我的意思是,市場上那些傳統競爭對手,我們在上一季已經承認他們的存在,我們認為必須這麼做,但就我們所見,第二季相較第三季並沒有任何根本性的變化。
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Okay. And then just on China, Joe. I get the sense that you just have improved visibility relative to kind of where you were sitting at this time last conference call. Is that the right kind of directional takeaway from the call as you see the trends into the fourth quarter? Clearly, it picked up in China in the third quarter. And what would you say, your long-range plan top line greater than 20% growth for the foreseeable future. What would you say your confidence level is kind of today versus maybe 3 months ago, particularly with -- now that you have more data points in hand on China and some of those North America trend last quarter that were in focus.
好的。接著談一下中國,Joe。我感覺相較於上次電話會議的這個時間點,你們現在的能見度有所提升。就你們觀察第四季的趨勢而言,這是否是本次電話會議正確的方向性結論?很明顯第三季在中國有所回升。另外你們的長期規劃是,在可預見的未來營收端維持 20% 以上的成長。你會怎麼形容你們目前的信心程度,相較於可能 3 個月前,尤其是——現在你們手上有更多中國的數據點,以及北美上季那些受到關注的趨勢。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Rich, I'll keep my comments kind of in this year. But I'd say, what China shaped up to be is pretty much what we called in the second quarter. We said the teen season is going to come in China. We thought that would be a lift. We've hired the salespeople. We're looking for that to take hold and be able to move the business forward. And so to say we have better visibility, I think we have the same visibility that we had quarter-to-quarter. Actually, from an execution standpoint, I just think the steps that we've taken with some of the pressure on consumer demand that we reported in the second quarter, the operational steps that we took in China on the ground, we're seeing a good result for it and we feel good about it.
Rich,我的評論先聚焦在今年。但我會說,中國的走勢基本上就是我們在第二季所預期的。我們說過中國會進入青少年旺季。我們認為那會帶來拉抬。我們已經聘用了業務人員。我們期待這些措施能夠發揮作用,推動業務向前。所以要說我們有更好的能見度,我認為我們的能見度與前幾季相比其實差不多。實際上,從執行面來看,我認為我們在第二季所提到的消費需求壓力之下,在中國當地採取的營運措施正在看到不錯的成果,我們對此感覺良好。
Operator
Operator
Our next question comes from Brandon Couillard with Jefferies.
下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Maybe just a couple of housekeeping items. Joe, any update on the timing of the U.S. approval for the 5D scanner? And then any color you can share with us as far as mandibular uptake in the U.S.?
可能先問幾個例行事項。Joe,關於 5D 掃描器在美國核准的時程,有沒有最新進度?另外,美國市場下顎(mandibular)的採用/滲透情況,你能否分享一些看法?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Brandon, on the 5D scanner, the FDA is the FDA, and we feel confident we'll get through here. Early part of next year would be the -- my best forecast in that sense. I could tell you, from a 5D standpoint, the uptick around the world has been good. The [carries] detection piece to be able to see cracks or deterioration in teeth has been terrific. And so it's really been a changing aspect to the clinical GP practice to be able to see carries in a way that you really can't see them without a near infrared technology. So we're actually really excited about that. And we're excited to get it into North America.
Brandon,關於 5D 掃描器,FDA 就是 FDA,我們有信心能順利通過。以目前來看,我最好的預估是明年年初。我可以告訴你,從 5D 的角度來看,全球的採用增長表現不錯。其中齲齒偵測功能,能看到牙齒裂紋或劣化的部分,效果非常好。因此,這確實正在改變一般牙科(GP)的臨床作業方式,因為透過近紅外線技術,你才能以過去做不到的方式看見齲齒。所以我們其實非常興奮。也很期待把它帶進北美。
Operator
Operator
Our next question comes from Jeff Johnson with Robert W. Baird.
下一個問題來自 Robert W. Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Joe, I want to go back to China, just you did talk last quarter that you would lose that kind of teen tailwind as you go into the fourth quarter and next kind of normalizes that to some adult patients and all that. But it sounds like, as you've said on this call, you're starting to see some good traction with some of the sales force adds and other efforts in that area. So should we look at Q2 as kind of that 26% number that you brought up again this quarter from 2Q, is that kind of where our -- the baseline should be from here, and you think, at least going forward, somewhere in there or above, given some of these recent efforts?
Joe,我想回到中國。你上季提到,進入第四季後會失去那種青少年旺季的順風,接下來會回到較正常的狀態、更多成人患者等等。但聽起來如你在本次電話會議所說,你們開始看到新增銷售團隊與其他努力帶來一些不錯的進展。所以我們是否應該把第二季你這季又提到的 26% 那個數字視為某種基準?也就是從現在起,我們的基準應該大致在那附近,並且你認為在這些近期努力之下,未來至少會在那個區間或更高?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, obviously, we feel -- we think we did well in the third quarter in China. Some of it was obviously the teen season. But actually, we had some pretty good adult growth, too. We're moving out of teen season there. As we talked about, the momentum going into the fourth quarter has been good there, too. As far as the baseline, Jeff, goes or whatever, hey, China is a growth market for us. We wouldn't be putting manufacturing in over there. We wouldn't be putting treatment planning, we wouldn't make the investments we're making, unless we feel that China is going to continue to be the second largest market that we're growing with. So I think that's the way you have to think about it going forward.
Jeff,很明顯,我們覺得——我們認為第三季在中國表現不錯。其中一部分當然是青少年旺季。但其實我們的成人成長也相當不錯。我們正在走出青少年旺季。如我們所談到的,進入第四季的動能在那邊也不錯。至於你說的基準或類似概念,Jeff,嘿,中國對我們來說是成長型市場。如果我們不認為如此,就不會在那邊設置製造。我們也不會在那邊做治療規劃,也不會進行我們正在做的投資,除非我們相信中國將持續成為我們成長中的第二大市場。所以我認為你未來應該用這樣的方式來看待。
What is it, Jeff?
怎麼了,Jeff?
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
There you are. Hang on. Sorry, what did you say?
我在。等一下。抱歉,你剛剛說什麼?
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
I said Shirley has got a quick hook tonight. So thank you for keeping me on for a follow-up...
我說 Shirley 今晚掛線很快。所以謝謝你讓我留下來追問……
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, we're trying to get to as many analysts as we can, but go ahead.
嗯,我們想盡量讓更多分析師提問,不過你繼續。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
She's upset about that with Wisconsin loss too, Jeff.
她也因為威斯康辛輸球而不高興,Jeff。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Well, as an Illinois fan, I won't comment on that. Joe, I do want to ask on the direct or kind of channel in the third quarter. Obviously, you've seen some states enact as your hurdles for some of those models and all that. I'm sure it's too early to see anything like that in your number or numbers. But I'd be interested, kind of what are you doing with your doctors to kind of try to combat some of that competition? Are you having any success in kind of helping these doctors understand where they need to be price point at? Is there other channel support you can provide? Just what are you doing to really kind of combat that direct-to-consumer angle?
嗯,身為伊利諾的球迷,我就不評論了。Joe,我確實想問第三季直銷或通路方面的情況。很明顯你們看到有些州把某些模式的門檻提高之類的。我確定現在要在你們的數字裡看到影響還太早。但我想了解的是,你們在醫師端做了哪些事情來對抗這類競爭?你們是否在協助這些醫師理解他們的定價應該落在哪個價位帶方面取得任何成效?是否還有其他通路支援可以提供?總之,你們到底在做什麼來真正對抗這種 DTC(直接面向消費者)的角度?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, I -- first of all, when we think about things that you're talking about, having a doctor in the center of this thing, having an X-ray, you're moving teeth through bone, people think that -- I think majority of people or patients out there think that teeth just hang from gums. They don't actually understand that the teeth are boned in. And actually seeing what's going on in the bone is a pretty good indicator if you should go through orthodontic treatment or not.
Jeff,我——首先,當我們思考你提到的這些事情時,讓醫師成為核心、做 X 光檢查是很重要的;你是在讓牙齒在骨頭裡移動。很多人——我想大多數人或患者以為牙齒只是掛在牙齦上。他們其實不了解牙齒是固定在骨頭裡的。而且實際看到骨頭裡的狀況,是判斷你是否應該接受矯正治療的一個很好的指標。
But with that said, with the GPs, I talked about in previous caller is the iGo product really is the best platform that we have right now in the sense of how to really educate doctors to go after these patients. And what I'm hearing more and more from GPs is they're having more and more of a dialogue with their patients. Their patients are coming in, they're asking questions now. They're saying, "Hey, what does this mean? What can you do for me? What's your price point for being able to straighten my six anterior teeth?" And we are trying to give them as many tools as we possibly can as far as workflow tools, which we have with iTero and iGo, and then products that they can really have a lot of confidence in.
但話說回來,對於一般牙科(GP),我在前一位提問者那裡提到,iGo 產品在目前來說確實是我們最好的平台,用來教育醫師如何去接觸這些患者。而我從 GP 那裡越來越常聽到的是,他們與患者之間的對話越來越多。患者會走進診所,他們現在會提問。他們會說:「嘿,這代表什麼?你能為我做什麼?如果要把我前面六顆牙齒拉直,你的價格是多少?」我們正盡可能提供他們更多工具,包括工作流程工具(我們透過 iTero 與 iGo 提供),以及他們能真正有高度信心的產品。
So I would say our initial push on that in United States has been improving significantly. You'll see it at the GP Summit, what we're rolling out and the kind of focus areas we have around that. But obviously, we'll have a very strong focus in that area, Jeff.
所以我會說,我們在美國對此的初期推動已經顯著改善。你會在 GP 峰會上看到我們正在推出的內容,以及我們在這方面的重點領域。但顯然,我們會在這個領域保持非常強的聚焦,Jeff。
Operator
Operator
Our next question comes from Elizabeth Anderson with Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
A lot of my questions at this point have been taken. But I just wanted to know if you could comment on the rise in inventory in the quarter? It seems like it just ticked up a little bit quarter-over-quarter but sort of has been rising year-over-year. And I just wanted to know if that was -- if there was something in what you guys were doing or something else behind that?
到目前為止,我的很多問題都已經被問過了。但我想了解你們能否評論一下本季庫存上升的情況?看起來它只是較上一季小幅增加,但同比似乎一直在上升。我想知道這是否是——你們正在做的某些事情所致,或背後還有其他原因?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Elizabeth, this is John. Really nothing out of the ordinary. When we look at the inventory, it's primarily on the iTero side. And it's really how we manufacture and much more level loading from a manufacturing standpoint. And really the rise that you saw in the third quarter is really anticipation of the volume that we expect in the fourth quarter. So that's all it is.
Elizabeth,我是 John。其實沒有什麼異常。我們看庫存時,主要是在 iTero 端。這主要與我們的製造方式有關,從製造角度來看更偏向於平準化生產負載。而你在第三季看到的上升,主要是因為我們預期第四季的出貨量而提前準備。就只是這樣。
Operator
Operator
Our next question comes from Matt O'Brien with Piper Jaffray.
下一個問題來自 Piper Jaffray 的 Matt O'Brien。
Andrew William Stafford - Research Analyst
Andrew William Stafford - Research Analyst
This is Drew on for Matt, and congrats on a nice quarter. I wanted to touch on consumer financing. I know you've talked about it a little bit in the past, and you're working through a third-party provider. Are you hearing any demand from customers asking for more options there? And would you have interest in expanding that program further?
我是 Drew,代替 Matt 提問,恭喜你們交出不錯的一季。我想談一下消費者融資。我知道你們過去稍微提過,而且你們是透過第三方供應商在運作。你們是否聽到客戶對更多選項的需求?你們是否有興趣進一步擴大這個計畫?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Drew, this is John. Of course, we want to do whatever we can to try to help turn those consumers into patients at a doctor. So financing is a piece of it. And we're working with companies, not just in the U.S. but other places as well, to try to remove some of that friction, give more options to those consumers, understand what the monthly payments are, how much down and so on. So there's a lot more that we can do there. We're making some progress, and you'll see new ways that we'll be coming to help, again, remove some of that friction for those consumers.
是的,Drew,我是 John。當然,我們希望盡一切可能協助把這些消費者轉化為到醫師那裡就診的患者。所以融資是其中一環。我們正與一些公司合作,不僅在美國,也在其他地區,試圖降低摩擦、為消費者提供更多選項,讓他們了解每月付款金額、首付款要多少等等。因此在這方面我們還能做得更多。我們正在取得一些進展,你們也會看到我們將以新的方式提供協助,再次降低這些消費者的摩擦。
Andrew William Stafford - Research Analyst
Andrew William Stafford - Research Analyst
Okay. And then just on the deal with Zimmer, maybe you could provide some thoughts on sort of why you chose them as a partner than maybe some of the geographies you'll be focusing on early on?
好的。另外關於與 Zimmer 的合作案,也許你可以談談為什麼選擇他們作為合作夥伴,以及你們初期會聚焦哪些地區?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Matt (sic) [Drew], it's Joe. On the Zimmer, we're really pleased to have them as partners. When you look at the history of that company from an implant standpoint, they're one of the leaders out there. They actually needed a digital front end, and that's what iTero really supply to them.
Matt(口誤)[Drew],我是 Joe。關於 Zimmer,我們很高興能與他們合作。從植體的角度看那家公司的歷史,他們是業界領導者之一。他們其實需要一個數位化的前端,而這正是 iTero 能提供給他們的。
When you look at our product line in conjunction with that, when you look at modern kind of treatments like that, implantology, is there's often a lot of space creation that has to take place in the sense of if a tooth is out of a mouth for a period of time, your teeth start to move over to fill that space. And more and more dentists do not want to remove enamel to put that implant in. So using aligners to be able to separate those teeth and allow an implant to be able to be a lot less invasive than it would be if you didn't account for that spacing.
再看我們的產品線與其結合,當你看這類現代治療方式,例如植牙學,往往需要進行所謂的空間創造:如果一顆牙齒缺失一段時間,其他牙齒會開始移動來填補那個空間。而且越來越多牙醫不希望為了植入植體而去磨除琺瑯質。因此使用隱形牙套把牙齒分開、創造空間,能讓植體植入比在未考量間隙的情況下更不具侵入性。
So overall, we're excited about it. I mean they're obviously strong all over the world. They complement us in so many places, including China. And so we're really excited about having a partnership, and we think we're starting off pretty well in the sense of the training and all that we reported.
所以整體而言,我們對此感到興奮。他們顯然在全球都很強。他們在很多地方都能與我們互補,包括中國。因此我們非常期待這個合作夥伴關係,而且就我們所報告的培訓等進展來看,我們認為起步相當不錯。
Operator
Operator
Our next question comes from Steven Valiquette with Barclays Bank.
下一個問題來自 Barclays Bank 的 Steven Valiquette。
Steven James Valiquette - Research Analyst
Steven James Valiquette - Research Analyst
So not to beat China to death here, but when you talked about some of the things you did to improve results over there, whether it was on the investments in the GP, dentist, sales force, sales program centered on Invisalign Go or even just the increased consumer marketing spend, I guess, I'm curious if any one of these variables really stood out as the driver of the improvement? Or was it a little bit of everything. And then also do you have any sort of high-level data points just on cases per doc in China on an absolute basis or even sort of relative to the rest of Align overall?
我不想在這裡把中國的話題講到膩,但當你談到你們為改善那邊的結果所做的一些事情——不論是對 GP、牙醫、銷售團隊的投資、以 Invisalign Go 為核心的銷售計畫,甚至只是增加消費者行銷支出——我想知道這些變數中是否有任何一項特別突出、成為改善的主要驅動因素?還是說是各種因素共同作用?另外,你們是否有任何高層級的數據點,關於中國每位醫師的病例數(cases per doc),不論是絕對值或相對於 Align 整體?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, on the variables of improvement, unfortunately, we're a multivariable equation when you get to aligners. Things are sold in binary here. But I think you do add a point to the 2 big ones, which would be just an increase in consumer focus and then the sales force that we put in place. That's -- our GP effort, we're just really moving into that too and we're arranging that properly also. But those efforts, we think, are contributing also. But I'd say it's a mix of those 3 variables. I can't weigh them for you, really.
Steve,關於改善的變數,很遺憾,在隱形牙套這件事上我們是一個多變數方程式。但事情在這裡常被用二元方式來看待。不過我認為你點出了兩個最大的因素:一是消費者端關注度的提升,二是我們建立起來的銷售團隊。至於我們的 GP 推動,我們也才剛真正開始切入,並且正在把架構安排到位。但我們認為那些努力也在貢獻改善。不過我會說這是這三個變數的組合。我真的沒辦法替你衡量各自的權重。
Steven James Valiquette - Research Analyst
Steven James Valiquette - Research Analyst
Okay. What about the cases per doc in China? Any color on that?
好的。那中國每位醫師的病例數呢?有沒有任何補充說明?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
No, we don't want to give any color on that one. Right now, it's just -- I'd say you have to look at it as we're driving penetration there, and we're training a lot of doctors as we ramp up in China.
不,我們不想對那個提供任何補充說明。目前我只能說,你必須把它視為我們正在推動那邊的滲透率,而且隨著我們在中國擴張,我們正在培訓大量醫師。
Operator
Operator
Our next question comes from Nathan Rich with Goldman Sachs.
下一個問題來自 Goldman Sachs 的 Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Just 2 quick ones here. First, on ASPs. I think guidance would put you at something like $1,250 for the year. Do you think you can kind of maintain that level of ASP going forward? And can you kind of just talk through what kind of the key factors would be as we think about ASPs going forward? And then just a very quick follow-up. John, just wondering if there was any catch-up benefit to cases in the quarter, kind of post that ClinCheck disruption that you highlighted in 2Q.
這裡兩個很快的問題。第一個,關於 ASP(平均售價)。我想指引看起來會讓你們全年大約落在 1,250 美元左右。你們認為未來能維持這個 ASP 水準嗎?以及能否談談我們在思考未來 ASP 時,關鍵影響因素會是什麼?然後再一個很快的追問。John,我想知道本季病例數是否有任何追趕效應的好處,算是你在第二季提到的 ClinCheck 中斷之後的回補?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Well, I'll start with that one first because there was really no catch-up or no benefit from that. As we had said in the second quarter call, it's really de minimis. There wasn't much of an effect that hit -- that affected the quarter. So there really wasn't an impact in the third quarter.
我先回答第二個,因為其實沒有任何追趕或回補帶來的好處。正如我們在第二季電話會議所說,影響非常微小(de minimis)。對本季造成影響的程度不大。所以第三季確實沒有影響。
In terms of ASPs, there's going to be puts and takes. And we've talked a number of times about what those puts and takes are. As we grow in comprehensive, like we had a strong comprehensive quarter in the third quarter, ASPs are higher, growing internationally, generally at a higher ASP.
至於 ASP,會有一些拉鋸因素。我們也多次談過這些拉鋸因素是什麼。當我們在 comprehensive(全口/完整療程)方面成長時——例如我們第三季 comprehensive 表現強勁——ASP 會更高;而國際市場的成長,一般而言 ASP 也較高。
But then you also have significant growth in the low stage, and that can affect the mix as well. So what we've said all year, and as we look at things, we thought it would be relatively consistent. The puts and takes would kind of offset. Notwithstanding any FX changes, we thought the puts and takes would offset. And we saw that in the third quarter and we are guiding that in the fourth quarter.
但接著你在低階段也會有顯著成長,這也可能影響產品組合。所以我們今年一整年所說的,以及我們在檢視各項情況時,我們原本認為會相對一致。各項增減因素大致會互相抵銷。撇除任何匯率(FX)變動,我們認為這些增減因素會互相抵銷。我們在第三季看到了這點,也在第四季的指引中反映這點。
Operator
Operator
Our next question comes from Michael Ryskin with Bank of America.
下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
I'll try to be brief. First, just one quick follow-on on the ASP. Obviously, really nice improvement in the third quarter. I was wondering if you've got any -- I realize it doesn't show up in the numbers, but maybe you've got some qualitative pushback or feedback from docs on the price increase, sort of what was the response there? Because this was the biggest quarter-over-quarter move in quite some time. And also maybe if you saw some divergence in results from some of your highest utilization docs that are getting the advantaged discounts that can absorb it versus some of the lower-tier docs that are paying more close to the full price and, therefore, maybe weighing some of the other doctor-directed options?
我會盡量簡短。首先,關於 ASP 再追問一個小問題。顯然第三季有非常不錯的改善。我想知道你們是否有任何——我知道這不會反映在數字上——但也許你們從醫師那邊收到一些對於漲價的質性反彈或回饋,他們的反應大概是什麼?因為這是相當長一段時間以來最大的季對季變動。另外,你們是否也看到一些結果上的分歧:例如使用量最高、享有較優惠折扣、因此更能吸收漲價的醫師,與一些較低層級、支付更接近全額價格、因此可能更傾向考量其他醫師導向選項的醫師之間?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Michael, it's Joe. On the ASP piece, obviously we raised price. John talked about it, some of the exchange aspect, whatever. But I think one thing I want the analysts who follow us to remember, like we said before, ASPs will fluctuate. But sometimes, our ASP is going down meaning our gross margins go up. Our lower-end products actually have a higher gross margin than our comprehensive product line. I know it's counterintuitive, but that's actually how it works.
Michael,我是 Joe。就 ASP 這部分,顯然我們有調漲價格。John 也談到了,包含一些匯兌方面的因素等等。但我想有一點我希望追蹤我們的分析師記住:如同我們之前說過的,ASP 會波動。但有時候,我們的 ASP 下降反而代表我們的毛利率上升。我們的低階產品實際上比我們的完整產品線有更高的毛利率。我知道這聽起來有點反直覺,但實際運作就是如此。
So I mean I think, keep that in mind going forward. If you see some of that lumpiness from an ASP standpoint start heading down, don't take as a trajectory for lower gross margin. It's just those 2 are separate that way. And John, do you want to add anything on your end?
所以我的意思是,之後請把這點放在心上。如果你看到 ASP 角度的某些波動開始往下走,不要把它解讀為毛利率走低的趨勢。只是這兩者在這方面是分開的。John,你那邊要補充什麼嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And so like we said, you're going to have some offsets, but we're trying to grow from a -- all the way from low stage, the more simple cases, all the way to the complicated cases. And we believe in those traditional orthodontic case starts that we have product that can help move teeth, but the market expansion and some of that market expansion is going to be at those lower-stage products that are at a lower ASP, but we look at that as incremental business for us.
所以如同我們所說,你會有一些抵銷因素,但我們正嘗試從——從低階段、較簡單的病例,一直到複雜病例——全面成長。我們相信在傳統的矯正病例啟動(case starts)方面,我們有能協助牙齒移動的產品;但市場擴張,以及其中一部分的市場擴張,將會發生在那些 ASP 較低的低階產品上,而我們把這視為對我們而言的增量業務。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
And on the -- quick follow-up on the EMEA headquarters move you mentioned in your prepared remarks, you're expecting some turnover in personnel. Any expectation for disruption to the business in early 2020, sort of how are you bracing for that? How are you preparing and just to make sure that it's a smooth transition going into January next year?
另外,針對你在事先準備的談話中提到的 EMEA 總部搬遷,再快速追問一下:你們預期會有人員流動。你們是否預期 2020 年初業務會受到干擾?你們打算如何因應?你們如何準備,以確保明年一月能順利銜接、平穩過渡?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, it's Joe again. Look, what we did in EMEA, which was fortuitous in a sense, about 3 years ago, we began to decentralize. We had a really big headquarters staff out of the Netherlands. It dictated a lot of what the regions did and had to do that because it's a relatively small business back then, and we needed to keep specialization at headquarters.
是的,我又是 Joe。你看,我們在 EMEA 做的事情,某種程度上算是因緣際會;大約 3 年前,我們開始去中心化。當時我們在荷蘭有一個非常龐大的總部團隊。它主導了各區域做什麼、必須做什麼;那時候業務規模相對較小,我們需要把專業能力集中在總部,所以必須那樣做。
Over the last 3 years, we really moved that out into the countries, moved it into France and Spain and Germany and different areas. And so we really embedded in those countries some real talent that I feel has good continuity will take them through. Now there's some overall headquarters talent that we don't want to lose that we're working hard to save, but I don't see it being a big, big disruptor for the business at all.
過去 3 年,我們真的把這些職能下放到各國,移到法國、西班牙、德國以及其他不同地區。因此我們在這些國家深度扎根了一些我認為具備良好延續性的優秀人才,能帶著團隊持續往前走。現在總部層面確實有一些人才我們不希望流失,我們也在努力留任,但我不認為這會對業務造成很大、很大的干擾。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And this has been something that -- Mike, this has been going on all year. We have a complete transition plan, very clear as to who's moving and how things are happening so that come January 1, it's very clear. So it's something that, as we've talked about on these calls since the beginning of the year, we've talked about this move and we feel really good about the plan that we have now and be able to hit the ground running in 2020.
而且這件事——Mike,這件事其實一整年都在進行。我們有一套完整的轉換計畫,非常清楚誰會搬遷、以及各項事情如何推進,讓 1 月 1 日到來時一切都非常明確。所以這是我們從年初以來在這些電話會議上就一直談到的事情;我們談過這次搬遷,也對目前的計畫感到非常有信心,能在 2020 年一開始就迅速展開工作。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you, everyone, for joining us today. This concludes our conference call. We look forward to seeing you at upcoming conferences and, of course, at the GP Summit in November. If you have any follow-on questions, please contact Madeline Homick in Investor Relations.
好的,感謝各位今天加入我們。本次電話會議到此結束。我們期待在接下來的各項會議上與各位見面,當然也包括 11 月的 GP Summit。若您有任何後續問題,請聯絡投資人關係部的 Madeline Homick。
Operator
Operator
This concludes today's conference. You may disconnect your lines at this time, and we thank you for your participation.
今天的會議到此結束。您現在可以掛斷電話線,感謝您的參與。